A283100 Stock Overview
Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Novomics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩813.00 |
| 52 Week High | ₩5,700.00 |
| 52 Week Low | ₩594.00 |
| Beta | 0 |
| 1 Month Change | -15.05% |
| 3 Month Change | -64.65% |
| 1 Year Change | -81.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| A283100 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 16.1% | 1.9% | 2.2% |
| 1Y | -81.0% | 6.5% | 5.4% |
Return vs Industry: A283100 underperformed the KR Biotechs industry which returned 6.5% over the past year.
Return vs Market: A283100 underperformed the KR Market which returned 5.4% over the past year.
Price Volatility
| A283100 volatility | |
|---|---|
| A283100 Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A283100's share price has been volatile over the past 3 months.
Volatility Over Time: A283100's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.novomics.com |
Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions. The company offers nProfiler1 Expansion Stomach Cancer Assay to analyze the gene expression profiles of stage II-III gastric cancer. It also provides nProfiler 2, a cancer variant assay; AI assisted digital pathology and auto sampling system; nProfiler, a breast cancer assay; nProfiler, a colon cancer assay; nProfiler, a rectal cancer assay; and nProfiler, a cOVID-19 detection kit.
Novomics Co., Ltd. Fundamentals Summary
| A283100 fundamental statistics | |
|---|---|
| Market cap | ₩5.31b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A283100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A283100 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A283100 perform over the long term?
See historical performance and comparison